-
1 Comment
Guangdong Taiantang Pharmaceutical Co., Ltd is currently in a long term uptrend where the price is trading 11.0% above its 200 day moving average.
From a valuation standpoint, the stock is 92.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.7.
Guangdong Taiantang Pharmaceutical Co., Ltd's total revenue sank by 8.9% to $886M since the same quarter in the previous year.
Its net income has dropped by 60.0% to $14M since the same quarter in the previous year.
Finally, its free cash flow fell by 120.3% to $-15M since the same quarter in the previous year.
Based on the above factors, Guangdong Taiantang Pharmaceutical Co., Ltd gets an overall score of 2/5.
| Industry | Drug Manufacturers-Specialty & Generic |
|---|---|
| Sector | Healthcare |
| ISIN | CNE100000Q92 |
| CurrencyCode | CNY |
| Exchange | SHE |
| Dividend Yield | 0.0% |
|---|---|
| Target Price | 14 |
| Market Cap | 3B |
| Beta | 0.39 |
| PE Ratio | None |
Guangdong Taiantang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of Chinese patent medicines in China. It offers medicines in the forms of creams, ointments, tablets, capsules, pills, and solutions for the areas, including reproductive health, skin health, cardiovascular, cerebrovascular, dermatology, anti-inflammatory, and other areas, as well as acquires, cultivates, processes, and sells Chinese medicinal materials. The company was founded in 1995 and is headquartered in Shantou, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 002433.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024
